Want to see TSE:APTX full AI Analyst Report?
Top Page
Apotex Health Corp.
(TSX:APTX)
Select Model
Select Model
Rating:61Neutral
Price Target:
C$36.00
▲(8.60% Upside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by improved profitability and strong, rising cash generation, but is held back by elevated balance-sheet risk (high debt and negative equity) and weak near-term technical momentum. Earnings call guidance and post-IPO deleveraging are supportive offsets, while valuation appears mid-range based on the provided P/E.
Positive Factors
Profitability turnaround
The move from losses to solid net and EBIT profitability shows meaningful operating improvement. Sustained margin expansion gives Apotex greater capacity to fund launches, absorb competitive pressure and strengthen its financial position.
Negative Factors
Highly leveraged balance sheet
The combination of materially higher debt and negative equity leaves Apotex with limited financial flexibility. Even with improving cash flow and post-IPO debt reduction, the stressed capital structure can constrain investment and increase refinancing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
The move from losses to solid net and EBIT profitability shows meaningful operating improvement. Sustained margin expansion gives Apotex greater capacity to fund launches, absorb competitive pressure and strengthen its financial position.
Read all positive factors
Apotex Health Corp. (APTX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$7.68B
Dividend Yield0%
Average Volume (3M)323.47K
Price to Earnings (P/E)20.9
Beta (1Y)-0.33
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees6,000
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding228,499,020
10 Day Avg. Volume247,993
30 Day Avg. Volume323,473
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-11.21
Price to Sales (P/S)1.79
P/FCF Ratio13.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$40.75Price Target Upside22.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Apotex Health Corp. Business Overview & Revenue Model
Company Description
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology bio...
Apotex Health Corp. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
34
Negative
Cash Flow
70
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 3.49B | 3.35B | 2.94B |
| Gross Profit | 1.94B | 1.79B | 1.10B |
| EBITDA | 911.77M | 668.03M | 161.91M |
| Net Income | 373.78M | 151.70M | -146.92M |
Balance Sheet | |||
| Total Assets | 4.54B | 4.85B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 56.99M | 77.97M | 421.35M |
| Total Debt | 3.52B | 2.65B | 1.87B |
| Total Liabilities | 5.10B | 4.56B | 3.31B |
| Stockholders Equity | -557.93M | 290.59M | 732.53M |
Cash Flow | |||
| Free Cash Flow | 458.98M | 310.33M | 459.38M |
| Operating Cash Flow | 640.96M | 554.41M | 570.90M |
| Investing Cash Flow | -177.07M | -627.87M | -2.70B |
| Financing Cash Flow | -483.46M | -279.19M | -281.67M |
Apotex Health Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$364.45M | 9.10 | 22.74% | ― | 3.18% | 140.09% | |
73 Outperform | C$204.98M | 7.53 | 25.79% | 2.48% | 2.96% | ― | |
67 Neutral | C$983.30M | 68.05 | 1.91% | ― | 42.32% | 4332.35% | |
63 Neutral | C$159.02M | -47.64 | -4.72% | ― | -3.16% | -345.50% | |
61 Neutral | C$7.68B | 20.89 | -279.63% | 0.00% | ― | ― | |
57 Neutral | C$3.39B | -2.22 | 88.77% | 5.04% | 9.12% | -1203.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
TSE:APTX
Apotex Health Corp.
33.63
6.63
24.56%
TSE:BHC
Bausch Health Companies
9.06
-1.06
-10.47%
TSE:GUD
Knight Therapeutics
10.01
3.56
55.19%
TSE:CPH
Cipher Pharmaceuticals
14.34
-2.45
-14.59%
TSE:CRRX
CareRx
3.23
0.28
9.38%
TSE:MDP
Medexus Pharmaceuticals Inc
5.06
1.94
62.18%
Apotex Health Corp. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Apotex Q1 2027 Results Show Strong Canadian Growth and Post-IPO Deleveraging
Positive
Aug 12, 2026
Apotex reported first-quarter Fiscal 2027 revenue of $848 million, broadly flat year over year once the prior contribution from generic Revlimid is excluded, with Canada leading growth at 11% on strong new product launches including semaglutide. A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.